Piper Sandler assumed coverage on shares of LENZ Therapeutics (NASDAQ:LENZ – Free Report) in a report released on Wednesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $28.00 price target on the stock.
LENZ Therapeutics Stock Performance
NASDAQ LENZ opened at $22.33 on Wednesday. The firm has a market cap of $185.83 million, a price-to-earnings ratio of -1.43 and a beta of 0.20. LENZ Therapeutics has a 1 year low of $14.07 and a 1 year high of $29.82.
Insider Activity at LENZ Therapeutics
In other LENZ Therapeutics news, Director Ra Capital Management, L.P. purchased 998,009 shares of the stock in a transaction on Thursday, March 21st. The shares were purchased at an average price of $15.03 per share, with a total value of $15,000,075.27. Following the completion of the transaction, the director now directly owns 3,319,339 shares in the company, valued at $49,889,665.17. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 38.40% of the stock is currently owned by company insiders.
About LENZ Therapeutics
Graphite Bio Inc is a clinical-stage, next-generation gene editing company focused on therapies to treat or cure serious diseases. Graphite Bio Inc is based in SOUTH SAN FRANCISCO, Calif.
Recommended Stories
- Five stocks we like better than LENZ Therapeutics
- Investing in Travel Stocks Benefits
- 3 Value Stocks Too Small For Buffett’s Portfolio
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- Airline Stocks – Top Airline Stocks to Buy Now
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
